[ad_1]
BIOCRATES Life Sciences AG – AAIC researchers report new data on the possible influence of intestinal bacteria and lipid metabolism on Alzheimer's disease and other neurological diseases
DGAP-News: Biocrates Life Sciences AG / Key Words] BIOCRATES Life Sciences AG – AAIC researchers report new data on
the possible influence of intestinal bacteria and lipid metabolism on Alzheimer's disease and other neurological disorders
25.07.2018 / 09:00
For the content of this announcement Issuer / publisher responsible.
—————————————— —– —————————-
BIOCRATES Life Sciences AG – AAIC researchers report new data [19659003] possible influence of intestinal bacteria and lipid metabolism on Alzheimer's disease and other neurological disorders
BIOCRATES technology allows the exploration of host interaction -microbiome
Innsbruck, Austria – July 25, 2018 – BIOCRATES Life Sciences AG, world leader in targeted metabolomics
today presented important new discoveries in the metabolomics of Alzheimer's Consortium
(Alzheimer's Disease Metabolomics Consortium, ADMC) in
Alzheimer's Research. The consortium established a link between
the gut-brain-brain axis and the development and progression of
Alzheimer's disease. At the International Conference of the Alzheimer's Association
(International Alzheimer's Association,
AAIC) in Chicago, USA, researchers presented new data on how intestinal bacteria and lipid metabolism could affect Alzheimer's disease.
Alzheimer's disease is a severe, progressive neurological disease
affecting more than 60 million
people worldwide. Despite great efforts, the cause of the disease
is still not fully understood. However, scientists
were able to show at the AAIC
held in Chicago this week that changes in bacterial intestinal flora or activity are badociated with cognitive and imaging changes in the brain
and atrophy
Patients with Alzheimer's correlate. This context
can also be applied to other neuropsychiatric disorders
.
Scientists presented new results obtained using the technology developed by BIOCRATES
to study host-microbiome interactions. could. It has been shown that
metabolic disorders of the liver and intestine correlate with cognitive decline
in patients with Alzheimer's. In addition, the results demonstrated a
effect of metabolic disorders in the liver and intestine on the pathological features of Alzheimer's disease, including inflammatory neurological effects
and amyloid-beta
The Alzheimer Consortium & Diseases Metabolomics Directed by Prof.
Rima Kaddurah-Daouk of Duke University Medical Center is an international consortium
of renowned academic institutions whose member
is also BIOCRATES. The ADMC was founded as part of the Accelerated Medicine Partnership of the NIA
on Alzheimer's Disease (AMP-AD) to study the pathogenic mechanisms
of Alzheimer's Disease. Alzheimer. The consortium maps
metabolic disorders during Alzheimer's disease and the contribution
of human metabolism and intestinal microbiota. Investigations
of Prof. Kaddurah-Daouk's Duke Medical Center show that the microbiome
in the intestine seems to play an important role in the pathogenesis of Alzheimer's disease
.
"BIOCRATES is pleased to be part of it The results
underline the importance of metabolism for the development of many diseases
and such results are possible only in the context of collaborations of large-scale research
The technology developed by us is for
such tailor-made collaborations, "commented Dr. Wulf
Fischer-Knuppertz, CEO of BIOCRATES." BIOCRATES will continue to develop
technologies to better understand the host microbiome
and its impact on the genesis and progression of diseases
such as Alzheimer's disease. "
The team of Prof. Kaddurah – Daouk showed in two separate studies involving more than 1,500 participants that patients with Alzheimer's in the blood produced lower levels of
primary bile acids produced by the liver (bile acids, BA) and c higher oncentrations of known bacteria and cells
secondary bile acids. In addition, Professor Kaddurah-Daouk
has shown for the first time that primary and secondary serum BA metabolites correlate with biomarkers [amyloidandneurodegenerative
for Alzheimer's disease: [c19659003] biomarkers of fluid Cerebrospinal (CSF) Cerebral atrophy
(by MRI) and glucose metabolism confirm the importance of bile acid metabolism
in the pathophysiology of the disease. Alzheimer.
Prof. Kaddurah-Daouk, Duke Psychiatry and the Institute of Brain Sciences,
added: "The new data indicate that the
intestine-liver-brain axis plays an important role in the development of memory loss
The badysis
of the metabolome could contribute to an early diagnosis of the disease
and allow effective therapies based on peripheral influences of the pathogenesis
of the brain, which could help determine
.]
AAIC press release of July 24, 2018: Advances
along the right-axis brain Axis in Alzheimer's disease: why the Diet can be so
Impactful
About AAIC
The International Alzheimer Association Conference (AAIC) is the world's
003] largest international gathering of scientists putting the focus on
Alzheimer's and d & # 39; 39, other diseases of dementia. As part of the research program of
Alzheimer's Association, the AAIC serves as a catalyst for generating new knowledge
on dementia and promoting a vibrant research community and
collegiate [19659004] AAIC 2018 Home Page: www.alz.org/ aaic
AAIC 2018 Press Section www.alz.org/aaic/press
About Duke University
Alzheimer Consortium & # 39; s Metabolomics (Alzheimer's Consortium & Disease Metabolomics
ADMC) under the direction of Prof. Dr. Rima Kaddurah Daouk at
Duke University is an ambitious initiative that combines representatives of
fundamental and clinical research specializing in Alzheimer's disease,
and works in close collaboration with research centers. excellence in metabolomics, genetics, biochemistry,
Technology and bioinformatics work together. Our goal is to identify
metabolic disorders throughout the disease
by grouping peripheral and central changes. We
identify changes in biochemical pathways and networks that can help us better understand the mechanisms of disease and to identify new targets
for drug development. We are part of national initiatives funded by the National Institutes on Aging
that include the Accelerated Medicine Partnership on Alzheimer's Disease (AMP-AD)
and the Molecular Mechanisms of Vascular Aetiology of Alzheimer's disease
. 19659003] (M2OVE-AD). Combining metabolomic data with genomics,
imaging and other comprehensive omic data in a biochemical systemic approach
we attempt to subdivided
the clbadification and treatment of Alzheimer's disease in a more precise medical approach. The results
of the metabolic profile of large cohorts of Alzheimer's and collaborative studies
are groundbreaking in the development of a national database
Alzheimer's and an atlas describing the Alzheimer's science
for the development of new drugs, All data generated by the consortium
will be made public. We are
partners of other consortiums integrated in AMP-AD and M2OVE, using
different types of large data to provide each other with information
and unprecedented opportunities to generate new hypotheses [19659003]
About the ADNI
The Alzheimer's Consortium's Metabolomics is badociated with the Neuroimaging Initiative of Alzheimer's Disease
(ADNI ) to provide all participants in the ADNI study
with complete metabolic recordings available for
. These metabolomic data sets are designed to inform metabolic disorders in all disease states and to supplement genetic and imaging data within the DNAI
. In phase 1, we profiled blood samples from the reference base
ADNI 1 / GO / 2 using eight complementary targeted metabolomics
and non-targeted lipidomic plateaus. In
phase 2, we will profile longitudinal samples of all ADNI studies with more than 5000 samples
. The ADNI is a public-private partnership
which launched in 2004 a longitudinal scientific study on
elderly people with Alzheimer's disease, mild cognitive impairment (MCI)
or without cognitive impairment
. 19659002] BIOCRATES Life Sciences AG was founded in 2002 and is a world leader
in the field of targeted metabolomics. The company
provides unique solutions for the quantitative determination and quality-controlled
of more than 400 endogenous metabolites
via kits and the quantitative determination of more than 800 metabolites as a mission service
]. BIOCRATES is an Austrian company headquartered in
Innsbruck and a subsidiary in the United States. During its development
of an academic spin-off to Metabolomics Company
BIOCRATES was selected by major financial and strategic investors
including MIG Fund and Bionorica S.E. supported. For more information, please visit www.biocrates.com or follow
on LinkedIn
For more information, contact:
BIOCRATES Life Sciences AG
Dr. Wulf Fischer-Knuppertz, CEO
T +43 512 57 98 23
MC Services AG
Dr. Claudia Gutjahr-Löser, Director General
T +49 89 210228-0
—————– ————————————————– ——–
25.07.2018 Dissemination of a Corporate News,
forwarded by DGAP – a service of EQS Group AG.
The content of this announcement is the exclusive property of the issuer / publisher.
Distribution services of the DGAP include regulatory announcements,
Company News / Financial News and Press Releases.
Media archive at http://www.dgap.de
————- —————— ——————————– ————
707665 25.07. 2018
°
Source link
